Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · INSMED Inc (INSM)

Insmed CFO Sara Bonstein to step down October 30; 2026 guidance reaffirmed

Neutral Impact 4 of 5 leadership Written later

Insmed said CFO Sara Bonstein will step down effective October 30, 2026, and the company has begun a search for a successor. The company said the departure is not related to any disagreement with Ms. Bonstein on accounting, financial statements, internal controls or operations. Insmed also reaffirmed full-year 2026 revenue guidance of $1.25 billion to $1.40 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE.

Key points

  • Ms. Bonstein remains CFO until October 30, 2026, and will participate in the third-quarter earnings call on October 29, 2026.
  • Insmed will release third-quarter 2026 results on October 29, 2026, with a conference call beginning at 8:00 a.m. ET.
  • Full-year 2026 guidance reaffirmed: BRINSUPRI revenue of $1.25 billion to $1.40 billion; ARIKAYCE revenue of $450 million to $470 million.
  • Chair and CEO Will Lewis said the company is well positioned to reach cash flow positivity next year.

The filing

CompanyINSMED Inc (INSM)
Form8-K, current report
Filed with the SECOct 5, 2026, 7:01 AM ET
Accession number0001140361-26-038529

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.